Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Gemcitabine and 5-FU in Advanced Cholangiocarcinoma
NCT03982680Phase 2Unknown
- Sponsor
- Jiangmen Central Hospital
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in cholangiocarcinoma (CCA), sponsored by Jiangmen Central Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03982680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982680.